All In Biotech

Drug Trial Radar · NCT00199368

An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018

A Long-Term, Multicenter, Open-Label Safety Study With Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy.

Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,100

Actual

Start

Oct 2004

Primary completion

Mar 2007

Study completion May 2007

Sponsor

Lead sponsor
Kyowa Kirin, Inc.Industry
Sponsor type
Industry
Collaborators
Kyowa Hakko Kirin UK, Ltd.
First posted
Sep 20, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.

Conditions

  • Parkinson's Disease

Interventions

  • Istradefylline ( KW-6002)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kyowa Pharmaceutical Inc.

    Princeton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.